kabutan

SANTEN PHARMA, Last Fiscal Year's Net Income Unexpectedly Increases, 7% Increase in The Current Fiscal Year, Dividend Raised by 4 Yen

Tue May 12, 2026 3:30 pm JST Earnings

4536 SANTEN PHARMACEUTICAL CO.,LTD. 【IFRS】

Earnings Report

SANTEN PHARMACEUTICAL CO.,LTD. <4536> [TSE Prime] announced its financial results (based on IFRS) after the market closed on May 12th (15:30). The consolidated net income for the fiscal year ended March 2026 increased by 3.1% from the previous period to 37.3 billion yen exceeding the previous forecast of 34.0 billion yen and resulted in an increase in profit, a complete reversal from the forecast for a decline in profit. For the fiscal year ending March 2027, the consolidated net income is expected to grow by 7.0% to 40.0 billion yen. This will be the third consecutive term of profit growth.

At the same time, the company has decided to increase the dividend this fiscal year to 42 yen, an increase of 4 yen from the previous fiscal year.

In the most recent three-month period, from January to March (4Q), the consolidated net income increased 76.9% from the same period last year, reaching 15.5 billion yen. The operating profit margin jumped from 15.1% in the same period last year to 24.2%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 301,965 38,541 29,874 26,642 72.6 33 May 9, 2024 IFRS
Mar, 2025 300,004 46,880 47,481 36,256 104.0 36 May 13, 2025 IFRS
Mar, 2026 291,624 47,797 47,442 37,369 114.0 38 May 12, 2026 IFRS
YoY -2.8% +2.0% -0.1% +3.1% +9.7%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Guidance 294,000 44,000 ー 34,000 105.7 38 Aug 7, 2025 IFRS
Mar, 2026 Results 291,624 47,797 47,442 37,369 114.0 38 May 12, 2026 IFRS
Revision Rate -0.8% +8.6% － +9.9% +7.9%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 137,879 17,915 17,634 13,940 41.8 19 Nov 6, 2025 IFRS
Apr - Sep, 2026 Guidance ー ー ー ー － 21 May 12, 2026 IFRS
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 300,004 46,880 47,481 36,256 104.0 36 May 13, 2025 IFRS
Mar, 2026 291,624 47,797 47,442 37,369 114.0 38 May 12, 2026 IFRS
Mar, 2027 Guidance 311,000 49,500 ー 40,000 124.4 42 May 12, 2026 IFRS
YoY +6.6% +3.6% － +7.0% +9.0%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2025 77,231 11,685 12,172 8,791 25.2 15.1 May 13, 2025 IFRS
Apr - Jun, 2025 68,737 7,573 7,450 5,878 17.3 11.0 Aug 7, 2025 IFRS
Jul - Sep, 2025 69,142 10,342 10,184 8,062 24.2 15.0 Nov 6, 2025 IFRS
Oct - Dec, 2025 72,884 10,304 10,442 7,876 23.9 14.1 Feb 5, 2026 IFRS
Jan - Mar, 2026 80,861 19,578 19,366 15,553 47.5 24.2 May 12, 2026 IFRS
YoY +4.7% +67.5% +59.1% +76.9% +88.3%

Related Articles